Pityriasis Lichenoides Chronica: Liver Involvement
Pityriasis lichenoides chronica (PLC) does not directly affect the liver, but rare case reports suggest possible associations with underlying liver disease, particularly autoimmune hepatitis and hepatitis C infection.
Disease Overview
PLC is a benign, chronic inflammatory skin disorder characterized by small, scaling papules that typically affect the trunk and extremities. It represents the chronic end of the pityriasis lichenoides spectrum, with lesions developing slowly and persisting for months to years 1, 2.
Liver Association: The Evidence
The relationship between PLC and liver disease is based on isolated case reports rather than systematic evidence:
Autoimmune hepatitis: One pediatric case report documented concurrent PLC with type I autoimmune hepatitis 3. The authors acknowledged uncertainty about whether this represented a true etiologic relationship or coincidental coexistence, though they suggested common immunologic mechanisms might be involved.
Hepatitis C: A single case report described PLC in a patient with chronic hepatitis C, with the authors noting that disease evolution during antiviral treatment suggested a possible pathogenetic link 4.
Critical caveat: These are isolated case reports from 2005-2007, representing the lowest level of evidence. No systematic studies, case series, or guidelines have established liver involvement as a recognized feature of PLC.
Clinical Implications
In routine practice, PLC should be considered a purely cutaneous disorder. Liver function testing is not indicated unless:
- The patient has independent risk factors for liver disease
- Systemic symptoms suggest extracutaneous involvement
- You are considering systemic treatments that require hepatic monitoring (methotrexate, acitretin, cyclosporine)
Treatment Considerations
When treating PLC, several systemic agents that do affect the liver may be used 5:
First-line: Narrow-band UVB phototherapy (no hepatic concerns)
Second-line systemic options (when phototherapy fails):
- Oral erythromycin: More effective in PLEVA than PLC (41.7% response rate in PLC vs 90.9% in PLEVA) 6
- Low-dose methotrexate: Requires baseline liver function tests and ongoing monitoring 7
- Topical corticosteroids: No hepatic monitoring needed
Important: If using methotrexate or other hepatotoxic agents, monitor liver function for drug-related hepatotoxicity, not because PLC itself affects the liver 7.
Bottom Line
PLC is a skin-limited disease. The two published case reports suggesting liver associations are insufficient to establish causality or warrant routine hepatic evaluation. Treat PLC as a dermatologic condition, and only investigate liver function if clinically indicated by other factors or required for medication monitoring.